The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis

Cutis

Volumn 79, Issue 1 SUPPL. 2, 2007, Pages 32-38

  Gold, Linda Stein ^a   Corvari, Linda ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b P value Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; CORTICOSTEROID; DRUG DERIVATIVE;

ARTICLE; DRUG COMBINATION; HUMAN; PATIENT COMPLIANCE; PSORIASIS; SAFETY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CHOLECALCIFEROL; DRUG THERAPY, COMBINATION; HUMANS; PATIENT COMPLIANCE; PSORIASIS; SAFETY; TREATMENT OUTCOME;

EID: 33846892536     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Feldman SR, Gelfand JM, Stein Gold L, et al. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79(suppl 1[ii]):18-31.
2. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-1912.
3. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-216.
4. Richards HL, Fortune DO, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-583.
5. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-414.
6. Callen JP, Krueger GG, Lebwohl M, et al, AAD. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003;49:897-899.
7. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol. 2000;42(5 pt 1):796-802.
8. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416-430.
9. Pearce DJ, Spencer L, Hu J, et al. Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat. 2004;15:235-238.
10. Pearce DJ, Stealey KH, Balkrishnan R, et al. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol. 2006;45:370-374.
11. Stern RS. Psoriasis. Lancet. 1997;350;349-353.
12. Baker H, Ryan TJ. Generalised pustular psoriasis, a clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80:771-775.
13. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol. 2002;3:141-147.
14. Wilkinson JM. Hypersensitivity to topical corticosteroids. Clin Exp Dermatol. 1994;19:1-11.
15. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol. 2004;93(suppl 2):S1-S21.
16. Wolkerstorfer A, Strobos MA, Glazenburg EJ, et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol. 1998;39:226-231.
17. Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br J Dermatol. 1998;139:763-766.
18. Hughes J, Rustin M. Corticosteroids. Clin Dermatol. 1997;15:715-721.
19. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111:581-583.
20. Miller JJ, Roling D, Margolis D, et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol. 1999;41:546-549.
21. Bruner CR, Feldman SR, Ventrapragada M, et al, A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003;9:2.
22. Salonen S-H, for the EUROPSO Patient Survey Study Group. The EUROPSO Psoriasis Patient Study: treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Available at: http://www.psori.fi/doc/patient_survey_1st_phase (2002).pdf. Accessed November 3, 2005.
23. Ashcroft DM, Po AL, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Br Med J. 2000;320:963-967.
24. Kragballe K. Calcipotriol: a new drug for topical psoriasis treatment. Pharmacol Toxicol. 1995;77:241-246.
25. Kawahara C, Okada Y, Tanikawa T, et al. Severe hypercalcemia and hypematremia associated with calcipotriol for treatment of psoriasis. J Bone Miner Metab. 2004;22:159-162.
26. Aaronson DW, Lebwohl M. Preview of therapy of psoriasis: the prebiologic armamentarium. Dermatol Clin. 2004;22:379-388.
27. Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol. 1998;39(4 pt 2):S134-S138.
28. 3 analogues. Dermatol Clin. 1994;13:835-839.
29. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139:649-654.
30. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35:268-269.
31. Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138:254-258.
32. Patel B, Siskin S, Krazmien R, et al. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol. 1998;38(6pt 1):1010-1011.
33. Koo JY. Using topical multimodal strategies for patients with psoriasis. Cutis. 2007;79(suppl 1[ii]):11-17.
34. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.
35. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriene in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.
36. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389-393.
37. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167-1173.
38. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-323.
39. Kragballe K, Austad J, Bames L, et al. A 52-week ran-domized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154:1155.1160.
40. Taclonex [package insert]. Rockaway, NJ: Warner Chilcott (US), Inc; 2006.
41. Balkrishnan R, Carroll CL, Camacho FT, et al. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol. 2003;49:651-654.
42. Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151:895-897.